Reports Q2 revenue $318.6M, consensus $304.21M. “In the second quarter, LivaNova achieved strong revenue and operating income growth,” said Vladimir Makatsaria, CEO of LivaNova. “Capitalizing on this momentum to achieve sustainable above-market growth over the long-term remains a key priority. I want to recognize our teams around the world for their continued execution and unwavering commitment to serving patients and customers. I also want to thank the consortium of independent experts who conducted an in-depth review of the RECOVER unipolar study results and supported the development of the path forward for the difficult-to-treat depression program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LIVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- LivaNova price target raised to $72 from $70 at Stifel
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Jefferies medical technology analyst holds analyst/industry conference call
- LivaNova’s Annual Meeting Strengthens Shareholder Alignment